ATE223224T1 - Neuartige peptide - Google Patents

Neuartige peptide

Info

Publication number
ATE223224T1
ATE223224T1 AT95926602T AT95926602T ATE223224T1 AT E223224 T1 ATE223224 T1 AT E223224T1 AT 95926602 T AT95926602 T AT 95926602T AT 95926602 T AT95926602 T AT 95926602T AT E223224 T1 ATE223224 T1 AT E223224T1
Authority
AT
Austria
Prior art keywords
oligopeptides
psa
novel peptides
free
assays
Prior art date
Application number
AT95926602T
Other languages
English (en)
Inventor
Deborah Defeo-Jones
Dong-Mei Feng
Victor M Garsky
Raymond E Jones
Allen I Oliff
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/267,092 external-priority patent/US5599686A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE223224T1 publication Critical patent/ATE223224T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Enzymes And Modification Thereof (AREA)
AT95926602T 1994-06-28 1995-06-07 Neuartige peptide ATE223224T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/267,092 US5599686A (en) 1994-06-28 1994-06-28 Peptides
US40483395A 1995-03-15 1995-03-15
PCT/US1995/008156 WO1996000503A1 (en) 1994-06-28 1995-06-07 Novel peptides

Publications (1)

Publication Number Publication Date
ATE223224T1 true ATE223224T1 (de) 2002-09-15

Family

ID=26952210

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95926602T ATE223224T1 (de) 1994-06-28 1995-06-07 Neuartige peptide

Country Status (26)

Country Link
US (1) US6143864A (de)
EP (1) EP0771209B1 (de)
JP (1) JPH10502619A (de)
KR (1) KR100379351B1 (de)
CN (1) CN1156964A (de)
AT (1) ATE223224T1 (de)
AU (1) AU689934B2 (de)
BG (1) BG63453B1 (de)
BR (1) BR9508151A (de)
CA (1) CA2192957A1 (de)
CZ (1) CZ381096A3 (de)
DE (1) DE69528064T2 (de)
DK (1) DK0771209T3 (de)
ES (1) ES2182908T3 (de)
FI (1) FI965225A7 (de)
HU (1) HU220877B1 (de)
MX (1) MX9700043A (de)
NO (1) NO965592L (de)
NZ (1) NZ290239A (de)
PL (1) PL186341B1 (de)
PT (1) PT771209E (de)
RO (1) RO116198B1 (de)
RU (1) RU2162855C2 (de)
SK (1) SK164096A3 (de)
UA (1) UA55371C2 (de)
WO (1) WO1996000503A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
DE69535665T2 (de) * 1994-08-19 2009-04-02 La Region Wallonne Konjugate enthaltend ein antitumorales mittel und deren verwendung
EP0855910A4 (de) * 1995-10-18 2000-07-05 Merck & Co Inc Verwendbare konjugate zur behandlung der gutartigen prostatehyperplasie
US5952294A (en) * 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6426075B1 (en) 1996-11-06 2002-07-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin A-like proproteins
US6545131B1 (en) 1997-05-19 2003-04-08 The Johns Hopkins University Tissue specific prodrug
US6504014B1 (en) 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
WO1998052966A1 (en) 1997-05-19 1998-11-26 The Johns Hopkins University School Of Medecine Tissue specific prodrug
US6391305B1 (en) * 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
PL197006B1 (pl) * 1997-12-02 2008-02-29 Merck & Co Inc Koniugat do leczenia raka prostaty, zawierająca go kompozycja farmaceutyczna i jej zastosowanie
JP2002505298A (ja) * 1998-03-05 2002-02-19 メルク エンド カムパニー インコーポレーテッド 前立腺癌治療に有用な結合体
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
MXPA01011008A (es) 1999-04-30 2003-06-30 Slil Biomedical Corp Conjugados analogos de poliamina y conjugados de quinona novedosos como terapia para canceres y enfermedades de la prostata.
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
CA2386669A1 (en) * 1999-10-07 2001-04-12 Ciphergen Biosystems, Inc. Prostate cancer marker proteins
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
CZ20022998A3 (cs) 2000-03-15 2003-05-14 Bristol-Myers Squibb Pharma Company Cílené antineoplastické léky a jejich terapeutické použití
AU2001266853B2 (en) 2000-06-14 2005-02-17 Medarex, Inc. Prodrug compounds with an oligopeptide having an isoleucine residue
AU2002235126A1 (en) 2000-11-08 2002-05-21 Slil Biomedical Corporation Novel polyamine analog-amino acid conjugates useful as anticancer agents
EP1219634A1 (de) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Glycokonjugate von Cytostatika mit einem geeigneten spaltbaren Peptidlinker
WO2002081630A2 (en) * 2001-04-06 2002-10-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of semenogelin in the diagnosis, prognosis and treatment of cancer
PT1567641E (pt) * 2001-08-24 2012-08-21 Uvic Industry Partnerships Inc Proaerolisina contendo sequência de activação de proteases e métodos de uso para o tratamento do cancro da próstata
WO2003046180A2 (en) * 2001-11-28 2003-06-05 Genset S.A. Human cdnas and proteins and uses thereof
US7108976B2 (en) * 2002-06-17 2006-09-19 Affymetrix, Inc. Complexity management of genomic DNA by locus specific amplification
KR101026294B1 (ko) * 2002-10-31 2011-03-31 메타베이시스 테라퓨틱스, 인크. 1,3-프로판-1-아릴 디올의 신규 시클릭 포스페이트디에스테르 및 프로드럭 제조에서의 이들의 용도
AU2003280688A1 (en) * 2003-10-31 2005-05-19 Kurume University Combination therapy of peptide vaccination and estramustine treatment
ES2366380T3 (es) 2005-06-14 2011-10-19 Protox Therapeutics Incorporated Método para el tratamiento o prevención de hiperplasia prostática benigna utilizando proteínas formadoras de poros modificadas.
JP5278873B2 (ja) * 2008-05-14 2013-09-04 国立大学法人九州工業大学 癌診断用試薬
WO2010117768A1 (en) * 2009-04-10 2010-10-14 The Regents Of The University Of California Prostatitis-associated antigens and methods of use thereof
KR20110069618A (ko) * 2009-12-17 2011-06-23 주식회사 셀앤바이오 전립선암 진단용 키트 및 진단방법
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4277466A (en) * 1978-08-29 1981-07-07 Institut International De Pathologie Cellulaire Et Moleculaire Complexes of DNA and esters derived from daunorubicine, their preparation and use
US4446122A (en) * 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
OA06421A (fr) * 1980-06-10 1981-09-30 Omnium Chimique Sa Procédé de préparation de dérivés N-(vinblastinoyl-23) d'acides aminés et de peptides.
DE3484691D1 (de) * 1983-04-29 1991-07-18 Omnichem Sa Konjugierte vinblastin-verbindungen und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
EP0126344A2 (de) * 1983-05-20 1984-11-28 Abbott Laboratories Tripeptidester von therapeutischen Mitteln
FR2583983B1 (fr) * 1985-06-07 1988-05-27 Centre Nat Rech Scient Nouvelles prodrogues macromoleculaires hydrosolubles, leur preparation et leur utilisation comme medicaments notamment antitumoraux et antiparasitaires
EP0232693A3 (de) * 1985-12-16 1988-04-06 La Region Wallonne Konjugate des Vinblastins und seiner Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5220001A (en) * 1989-10-25 1993-06-15 Zaidan Hojim Biseibutsu Dong-A Pharm Co. Anthracycline glycoside derivatives
IT1241927B (it) * 1990-05-14 1994-02-01 Menarini Farma Ind 3'-deamino-4'-deossi-4'-amino-8-fluoroantra- cicline processi per la loro preparazione e composizioni farmaceutiche che le contengono
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0513388A4 (en) * 1990-11-30 1993-06-30 Asahi Glass Company Ltd. Peptide with activity of inhibiting cancer cell infiltration, composite thereof, and cancer metastasis inhibitor
FR2678274A1 (fr) * 1991-06-25 1992-12-31 Medgenix Group Sa N-leucyl epirubicine application a titre de medicament antitumoral et procede de preparation.
US5288612A (en) * 1991-07-03 1994-02-22 The Scripps Research Institute Assay methods for detecting serum proteases, particularly activated protein C
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
ES2191018T3 (es) * 1992-10-29 2003-09-01 Univ Jefferson Procedimiento para detectar micrometastasis de cancer de prostata.
WO1994020114A1 (en) * 1993-03-12 1994-09-15 Board Of Regents, The University Of Texas System Anthracyclines with unusually high activity against cells resistant to doxorubicin and its analogs
GB9320191D0 (en) * 1993-09-30 1993-11-17 Univ Napier Compounds
AU699748B2 (en) * 1994-05-10 1998-12-10 Hybritech Incorporated Recombinant HK2 polypeptide
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
DE69535665T2 (de) * 1994-08-19 2009-04-02 La Region Wallonne Konjugate enthaltend ein antitumorales mittel und deren verwendung
AUPM769394A0 (en) * 1994-08-25 1994-09-15 Commonwealth Scientific And Industrial Research Organisation Assay for the detection of proteases

Also Published As

Publication number Publication date
DK0771209T3 (da) 2002-10-07
NO965592L (no) 1997-02-28
AU3092295A (en) 1996-01-25
EP0771209A2 (de) 1997-05-07
BR9508151A (pt) 1999-03-30
NZ290239A (en) 1998-11-25
UA55371C2 (uk) 2003-04-15
EP0771209B1 (de) 2002-09-04
PL186341B1 (pl) 2003-12-31
BG101077A (bg) 1998-02-27
FI965225L (fi) 1997-02-26
HUT76350A (en) 1997-08-28
HU9603564D0 (en) 1997-02-28
BG63453B1 (bg) 2002-02-28
CA2192957A1 (en) 1996-01-11
SK164096A3 (en) 1997-06-04
DE69528064D1 (de) 2002-10-10
RU2162855C2 (ru) 2001-02-10
MX9700043A (es) 1997-04-30
KR100379351B1 (ko) 2003-10-30
EP0771209A4 (de) 2000-04-26
HK1009038A1 (en) 1999-07-02
KR970703780A (ko) 1997-08-09
DE69528064T2 (de) 2003-08-07
CZ381096A3 (en) 1997-04-16
AU689934B2 (en) 1998-04-09
JPH10502619A (ja) 1998-03-10
CN1156964A (zh) 1997-08-13
ES2182908T3 (es) 2003-03-16
PL317872A1 (en) 1997-04-28
RO116198B1 (ro) 2000-11-30
US6143864A (en) 2000-11-07
NO965592D0 (no) 1996-12-27
FI965225A0 (fi) 1996-12-27
PT771209E (pt) 2002-12-31
HU220877B1 (en) 2002-06-29
FI965225A7 (fi) 1997-02-26
WO1996000503A1 (en) 1996-01-11

Similar Documents

Publication Publication Date Title
ATE223224T1 (de) Neuartige peptide
WO1996000503B1 (en) Novel peptides
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
CY1109614T1 (el) Μορια παρομοια με παραγοντα vii ή viia
HUP0204475A2 (en) Enhancing the circulating half-life of antibody-based fusion proteins
DE69332879D1 (de) Technetium-99-markierte peptide zur visualisierung vom entzuendungen
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
DE69109109D1 (de) Ubiquitinspezifische protease.
ATE325625T1 (de) Technetium-99m markierte peptide zur diagnostischen bilderzeugung von entzündungen
IL139478A0 (en) Hybrid protein
EP1116029A4 (de) Antikörper für apoptosemarker und anwendungsverfahren
DK0387231T3 (da) Hidtil ukendte inhibitorer for retroviral protease
YU21399A (sh) Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže
EP1009420A4 (de) Konjugate welche bei der behandlung von prostatakrebs nützlich sind
NO20025064L (no) RGO koblet til peptider
TR199900940T2 (xx) Helikobakter pilori ile ilgili n�kleik ve amino asit sekanslar�.
Sanchez et al. Proteolytic specificity of two hemorrhagic factors, LHF-I and LHF-II, isolated from the venom of the bushmaster snake (Lachesis muta muta)
HUP9800782A2 (hu) Új antitest, az azt tartalmazó renin-aktív anyag és a prorenin vizsgálatára szolgáló reagens
KR900702017A (ko) 혼성 단백질(bybrid proteins)
Wojtecka-Łukasik et al. Effects of neutral proteases from human leukocytes on plasma fibronectin
EP1796707A4 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
Marks et al. Enzymes in the metabolism of opioid peptides: isolation, assay, and specificity
MXPA03010785A (es) Celulas hospedero caulobacter deficientes de proteasa.
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
TR199701538T1 (xx) Helibakter pilor'un n�kleik asit ve amino asit sekanslar�.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee
EEWE Authorization for restitution
REN Ceased due to non-payment of the annual fee